{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:04:23Z","timestamp":1782839063911,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation, China","doi-asserted-by":"crossref","award":["81973411"],"award-info":[{"award-number":["81973411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Research and Development Project of Shaanxi Province, China","award":["2023-YBSF-225"],"award-info":[{"award-number":["2023-YBSF-225"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver disease worldwide, making efficient targeted delivery systems essential to alleviate its socioeconomic burden. Aptamers are short, single-stranded DNA or RNA oligonucleotides that bind to specific target antigens with high affinity and specificity. Compared with antibody-based therapies, aptamer-based therapies offer the advantages of small size, facile synthesis and low immunogenicity. Herein, we report a novel fatty acid translocase CD36-targeted aptamer\u2212drug conjugate (ApDC), the NAFLD01 aptamer conjugated with 4-(4-(tert-butyl)benzoyl)-2,3-dihydroxyphenyl furan-2-carboxylate (SF), termed ASC, as a targeted delivery platform for MASLD. Results demonstrated that SF significantly reduced body weight, attenuated liver injury and ameliorated lipid accumulation in high-fat diet (HFD)-induced MASLD mice. ASC effectively reduced lipid droplet formation and hepatic injury biomarker levels, while improving antioxidant enzyme levels in MASLD cell models in vitro. A key advantage of ASC is its capacity for targeted SF delivery, which potentially reduces off-target exposure of SF to non-target organs. ASC retained the intrinsic properties of the NAFLD01 aptamer, including high binding affinity and efficient internalization by target cells. Additionally, the acid-labile hydrazone bond in ASC was cleaved in an acidic lysosomal environment. In conclusion, ASC is a promising ApDC delivery platform for MASLD.<\/jats:p>","DOI":"10.1093\/rb\/rbag104","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:44:56Z","timestamp":1780141496000},"source":"Crossref","is-referenced-by-count":1,"title":["A CD36-targeted aptamer-4-butyl-polyhydroxybenzophenone conjugate with pH-responsive release for liver delivery in MASLD"],"prefix":"10.1093","volume":"13","author":[{"given":"Luyao","family":"Ren","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Shanxi Medical University , Taiyuan 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026062812113923300_rbag104-B1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.14844","article-title":"New drugs for NASH","volume":"41","author":"Albhaisi","year":"2021","journal-title":"Liver Int"},{"key":"2026062812113923300_rbag104-B2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026062812113923300_rbag104-B3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/biom15010140","article-title":"Drug advances in NAFLD: individual and combination treatment strategies of natural products and small-synthetic-molecule drugs","volume":"15","author":"Wan","year":"2025","journal-title":"Biomolecules"},{"key":"2026062812113923300_rbag104-B4","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1038\/s41467-023-40327-5","article-title":"Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"key":"2026062812113923300_rbag104-B5","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.2147\/IJN.S510271","article-title":"Therapeutic nanomaterials in NAFLD: current advances and potential applications in patients with concurrent HBV infection","volume":"20","author":"Li","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"2026062812113923300_rbag104-B6","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1039\/D2FO04036K","article-title":"Hepatic parenchymal cell and mitochondrial-targeted astaxanthin nanocarriers for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"14","author":"Che","year":"2023","journal-title":"Food Funct"},{"key":"2026062812113923300_rbag104-B7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1166\/jbn.2020.2943","article-title":"Advances in aptamer screening and drug delivery","volume":"16","author":"Tang","year":"2020","journal-title":"J Biomed Nanotechnol"},{"key":"2026062812113923300_rbag104-B8","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026062812113923300_rbag104-B9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms18091851","article-title":"Potential diagnostic and therapeutic applications of oligonucleotide aptamers in breast cancer","volume":"18","author":"Wu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026062812113923300_rbag104-B10","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2174\/0929867325666181008142831","article-title":"Aptamer-based targeted drug delivery systems: current potential and challenges","volume":"27","author":"He","year":"2020","journal-title":"Curr Med Chem"},{"key":"2026062812113923300_rbag104-B11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/5584_2022_732","article-title":"Aptamer-based tumor-targeted diagnosis and drug delivery","volume":"1409","author":"Woldekidan","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"2026062812113923300_rbag104-B12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1039\/D0BM01832E","article-title":"Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer","volume":"9","author":"Ge","year":"2021","journal-title":"Biomater Sci"},{"key":"2026062812113923300_rbag104-B13","doi-asserted-by":"crossref","first-page":"155914","DOI":"10.1016\/j.metabol.2024.155914","article-title":"O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36","volume":"156","author":"Zhu","year":"2024","journal-title":"Metabolism"},{"key":"2026062812113923300_rbag104-B14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41419-022-04812-x","article-title":"B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026062812113923300_rbag104-B15","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/s41467-021-27539-3","article-title":"The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"2026062812113923300_rbag104-B16","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1021\/acs.analchem.0c04866","article-title":"CD36 as a molecular target of functional DNA aptamer NAFLD01 selected against NAFLD cells","volume":"93","author":"Pu","year":"2021","journal-title":"Anal Chem"},{"key":"2026062812113923300_rbag104-B17","doi-asserted-by":"crossref","first-page":"115728","DOI":"10.1016\/j.ejmech.2023.115728","article-title":"SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of 4-butyl-polyhydroxybenzophenone compounds against NAFLD","volume":"260","author":"Song","year":"2023","journal-title":"Eur J Med Chem"},{"key":"2026062812113923300_rbag104-B18","doi-asserted-by":"crossref","first-page":"156458","DOI":"10.1016\/j.phymed.2025.156458","article-title":"Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder","volume":"139","author":"Zhou","year":"2025","journal-title":"Phytomedicine"},{"key":"2026062812113923300_rbag104-B19","doi-asserted-by":"crossref","first-page":"119330","DOI":"10.1016\/j.jep.2025.119330","article-title":"Aqueous extract of Cornus officinalis alleviate NAFLD via protecting hepatocytes proliferation through regulation of the tricarboxylic acid cycle","volume":"341","author":"Liu","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"2026062812113923300_rbag104-B20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/jm020406h","article-title":"Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine","volume":"46","author":"Jain","year":"2003","journal-title":"J Med Chem"},{"key":"2026062812113923300_rbag104-B21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1039\/D1RA05799E","article-title":"Exploring the potential therapeutic effect of Eucommia ulmoides-Dipsaci Radix herbal pair on osteoporosis based on network pharmacology and molecular docking technology","volume":"12","author":"Feng","year":"2022","journal-title":"RSC Adv"},{"key":"2026062812113923300_rbag104-B22","doi-asserted-by":"crossref","first-page":"3782230","DOI":"10.1155\/2023\/3782230","article-title":"Highly accessible computational prediction and in vivo\/in vitro experimental validation: novel synthetic phenyl ketone derivatives as promising agents against NAFLD via modulating oxidoreductase activity","volume":"2023","author":"Qiao","year":"2023","journal-title":"Oxid Med Cell Longev"},{"key":"2026062812113923300_rbag104-B23","doi-asserted-by":"crossref","first-page":"154798","DOI":"10.1016\/j.metabol.2021.154798","article-title":"Fenofibrate, a PPAR\u03b1 agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy","volume":"120","author":"Yoo","year":"2021","journal-title":"Metabolism"},{"key":"2026062812113923300_rbag104-B24","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/acs.molpharmaceut.9b00188","article-title":"Targeted delivery of a ligand-drug conjugate via formyl peptide receptor 1 through cholesterol-dependent endocytosis","volume":"16","author":"Wang","year":"2019","journal-title":"Mol Pharm"},{"key":"2026062812113923300_rbag104-B25","doi-asserted-by":"crossref","first-page":"15459","DOI":"10.1002\/anie.202102631","article-title":"Enhancing anti-PD-1 immunotherapy by nanomicelles self-assembled from multivalent aptamer drug conjugates","volume":"60","author":"Geng","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"2026062812113923300_rbag104-B26","doi-asserted-by":"crossref","first-page":"G341","DOI":"10.1152\/ajpgi.00163.2022","article-title":"ATF4-mediated CD36 upregulation contributes to palmitate-induced lipotoxicity in hepatocytes","volume":"324","author":"Griffiths","year":"2023","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026062812113923300_rbag104-B27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"2026062812113923300_rbag104-B28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1432-1033.2003.03929.x","article-title":"Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells","volume":"271","author":"Legrand","year":"2004","journal-title":"Eur J Biochem"},{"key":"2026062812113923300_rbag104-B29","doi-asserted-by":"crossref","first-page":"113655","DOI":"10.1016\/j.yexcr.2023.113655","article-title":"Oleic acid improves hepatic lipotoxicity injury by alleviating autophagy dysfunction","volume":"429","author":"Liu","year":"2023","journal-title":"Exp Cell Res"},{"key":"2026062812113923300_rbag104-B30","doi-asserted-by":"crossref","first-page":"113680","DOI":"10.1016\/j.jconrel.2025.113680","article-title":"Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease","volume":"382","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"2026062812113923300_rbag104-B31","doi-asserted-by":"crossref","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"2026062812113923300_rbag104-B32","doi-asserted-by":"crossref","first-page":"124173","DOI":"10.1016\/j.ijbiomac.2023.124173","article-title":"Advances in aptamer-mediated targeted delivery system for cancer treatment","volume":"238","author":"He","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"2026062812113923300_rbag104-B33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/cancers15030922","article-title":"Targeted-lymphoma drug delivery system based on the Sgc8-c aptamer","volume":"15","author":"Sicco","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026062812113923300_rbag104-B34","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer","volume":"142","author":"He","year":"2020","journal-title":"J Am Chem Soc"},{"key":"2026062812113923300_rbag104-B35","doi-asserted-by":"crossref","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026062812113923300_rbag104-B36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"2026062812113923300_rbag104-B37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3390\/biom14111445","article-title":"Exploring PPAR gamma and PPAR alpha\u2019s regulation role in metabolism via epigenetics mechanism","volume":"14","author":"Ma\u0142odobra-Mazur","year":"2024","journal-title":"Biomolecules"},{"key":"2026062812113923300_rbag104-B38","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.2147\/DDDT.S386982","article-title":"Biological mechanisms and related natural inhibitors of CD36 in nonalcoholic fatty liver","volume":"16","author":"Feng","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2026062812113923300_rbag104-B39","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026062812113923300_rbag104-B40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J Hepatol"},{"key":"2026062812113923300_rbag104-B41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2026062812113923300_rbag104-B42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2022.07.010","article-title":"Impact of NAFLD and its pharmacotherapy on lipid profile and CVD","volume":"355","author":"Wang","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026062812113923300_rbag104-B43","doi-asserted-by":"crossref","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-Alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026062812113923300_rbag104-B44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cbic.200800805","article-title":"Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells","volume":"10","author":"Huang","year":"2009","journal-title":"Chembiochem"}],"container-title":["Regenerative Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rb\/advance-article-pdf\/doi\/10.1093\/rb\/rbag104\/68446008\/rbag104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rb\/article-pdf\/doi\/10.1093\/rb\/rbag104\/68446008\/rbag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rb\/article-pdf\/doi\/10.1093\/rb\/rbag104\/68446008\/rbag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:11:53Z","timestamp":1782663113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rb\/article\/doi\/10.1093\/rb\/rbag104\/8699603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1093\/rb\/rbag104","relation":{},"ISSN":["2056-3418","2056-3426"],"issn-type":[{"value":"2056-3418","type":"print"},{"value":"2056-3426","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rbag104"}}